An ultra-fast-acting mealtime insulin — dubbed Ultra Rapid Lispro, or URLi — reduced HbA1c as well as insulin lispro and significantly improved postprandial glucose levels in adults with type 1 and type 2 diabetes, according to a press release from Eli Lilly.
In the 26-week PRONTO-T1D and PRONTO-T2D phase 3 safety and efficacy trials, URLi was shown to be noninferior to insulin lispro (Humalog, Lilly) in reducing HbA1c from baseline and better at reducing glucose excursions at 1 hour and 2 hours after meals in participants with type 1 diabetes (n = 1,222) and type 2 diabetes (n = 673), according to the release. URLi and Humalog had similar safety profiles, Lilly announced.
“Despite progress in insulin and diabetes management, many people with diabetes find controlling high blood sugar levels after meals frustrating. If approved, URLi will be a new option in mealtime insulin therapy designed to help keep blood sugar in range after eating,” Thomas Hardy, senior medical director for insulins product development at Lilly Diabetes, said in the release.
Lilly will present the study results and apply for FDA approval in 2019, according to the release.